Treatment of cancer therapy-induced oral mucositis

Streptococcus salivarius for use in the treatment or prevention of an ear, nose, and throat (ENT) disease, which is induced by or associated with an immunosuppression, preferably wherein the ENT disease is an oral mucosa disorder or a respiratory tract infection.

Streptococcus salivarius for use according to claim 26, wherein the lozenge further comprises fructose, maltodextrin, magnesium stearate and a flavor, preferably strawberry flavor.

Streptococcus salivarius for use according to claim 25 or 36, wherein the lozenge is a slow dissolving lozenge, preferably wherein the disintegration time of the lozenge is at least 4 to 5 minutes.

A composition comprising Streptococcus salivarius for use in the treatment or prevention of an ear, nose, and throat (ENT) disease which is induced by or associated with a cancer therapy.

A composition comprising Streptococcus salivarius for use in the treatment or prevention of an ear, nose, and throat (ENT) disease, which is induced by or associated with an immunosuppression, preferably wherein the ENT disease is an oral mucosa disorder or a respiratory tract infection.

Use of a composition comprising Streptococcus salivarius in the maintenance of healthy oral mucosa of a subject during treatment with a cancer or autoimmune disease therapy, during treatment with radiotherapy, chemotherapy, hematopoietic stem cell transplantation (HSCT), immune checkpoint inhibitor therapy, or any combination thereof, or of a subject which is immunosuppressed.

Streptococcus salivarius or a composition comprising Streptococcus salivarius for use in the treatment or prevention of a respiratory tract infection in a human subject, wherein the human subject is immunosuppressed.

A method of treating or preventing an ear, nose, throat (ENT) disease which is induced by or associated with a cancer therapy in a subject in need thereof, wherein the method comprises administering Streptococcus salivarius or a composition comprising Streptococcus salivarius to the subject.

Use of Streptococcus salivarius or a composition comprising Streptococcus salivarius in the manufacturing of a medicament for treating or preventing an ear, nose, throat (ENT) disease which is induced by or associated with a cancer therapy in a subject in need thereof.

A method of treating or preventing a respiratory tract infection in a human subject, wherein the human subject is immunosuppressed, the method comprising administering Streptococcus salivarius or a composition comprising Streptococcus salivarius to the subject.